Abp 234 vs MB12
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Abp 234
Developed by Amgen
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06430866 (registry estimate)
No aligned efficacy figure on record for this race.
MB12
Developed by Laboratorio Elea Phoenix S.A. and partners
NCT05668650 · Phase 3 · status unknown
This is a randomized, double-blind, active-controlled trial with over 170 patients, but its primary comparison is a pharmacokinetic equivalence check between MB12 and the reference drug rather than a clinical efficacy comparison. No results have been posted yet.
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Abp 234 | MB12 |
|---|---|---|
| PFS, median | —Trial running · NCT06430866 | —Trial running · NCT06687369 |
| OS, median | —Trial running · NCT06430866 | —Trial running · NCT06687369 |
| ORR | —Trial running · NCT06430866 | —Trial running · NCT06687369 |
| Duration of response, median | —Trial running · NCT06430866 | —Trial running · NCT06687369 |
PFS, median
- Abp 234
- —Trial running · NCT06430866
- MB12
- —Trial running · NCT06687369
OS, median
- Abp 234
- —Trial running · NCT06430866
- MB12
- —Trial running · NCT06687369
ORR
- Abp 234
- —Trial running · NCT06430866
- MB12
- —Trial running · NCT06687369
Duration of response, median
- Abp 234
- —Trial running · NCT06430866
- MB12
- —Trial running · NCT06687369
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Abp 234: no structured comparison results are available for Non-Small Cell Lung Cancer.
MB12: no structured comparison results are available for Non-Small Cell Lung Cancer.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Abp 234's landscape · MB12's landscape